vincristine + daunorubicin + asparaginase + methotrexate

A combination chemotherapy regimen used primarily in the treatment of acute lymphoblastic leukemia (ALL). This multi-drug protocol typically includes: - **Vincristine**: A vinca alkaloid that binds to tubulin and inhibits microtubule assembly, preventing cell division - **Daunorubicin**: An anthracycline that intercalates with DNA and inhibits topoisomerase II - **Asparaginase**: An enzyme that depletes asparagine, which leukemic cells cannot synthesize on their own - **Methotrexate**: An antimetabolite that inhibits dihydrofolate reductase, preventing DNA synthesis This combination is administered in different phases of ALL treatment, including induction, consolidation, and maintenance therapy. The specific dosing and scheduling may vary based on treatment protocols, risk stratification, and patient characteristics.